The Latest Breaking News from HIV

The World Health Organization’s 2024 Global Tuberculosis report reveals a sobering reality. Formidable challenges remain in the fight against the world’s most infectious disease: persistent poverty in high burden countries; increased rates of infection among vulnerable populations; the inability to find and treat all missing cases; and funding shortfalls.

Clients of now closed Fresh Cosmetic Clinic warned to get tested after possible exposure to blood-borne viruses such as hepatitis B, hepatitis C or HIV

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

On Call, Anthony Fauci's new memoir, can't disguise the damage caused by his COVID-19 policies.

A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months.

Condom usage is down among teens and young adults in the U.S. Medical advancements, a fading fear of contracting HIV and widely varying degrees of sex education in high schools all contribute to the trend

Condom use is down among sexually active teens and young adults

The Duke of Sussex spoke on a trip to South Africa to promote his HIV charity Sentebale

The biotech sector is booming, fueled by rising healthcare demands, exciting advancements in technology, and increased FDA drug approvals. Thus, investing in Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), and Gilead Sciences (GILD) could be a golden opportunity for those looking to ride the wave of future breakthroughs. Read on….